Affordable Access

Protein kinases in drug discovery and development.

Authors
  • Hadari, Y R
Type
Published Article
Journal
IDrugs : the investigational drugs journal
Publication Date
Dec 01, 2001
Volume
4
Issue
12
Pages
1329–1332
Identifiers
PMID: 15931557
Source
Medline
License
Unknown

Abstract

The Protein Kinases in Drug Discovery and Development meeting highlighted protein kinases as validated therapeutic targets in many types of disease, especially cancer. Drugs designed to inhibit protein kinase activity were widely tested in preclinical and clinical evaluation, demonstrating significant efficacy with acceptable toxicity profiles. More than 600 kinases are encoded by the human genome, some of which are already well established as validated targets due to extensive scientific research from both academic institutions and industrial companies. As demonstrated by several speakers during the meeting, different diseases exhibit mutations or over-expression of the same kinase. Therefore, a drug designed to inhibit these specific kinases can potentially be used as a therapeutic agent in the treatment of more then one disease. The major strategy employed by most companies today in drug discovery is using genomic information, together with clinical research, to identify novel potential targets. A drug discovery project is then established around the chosen target kinase, in order to identify, optimize and deliver novel potential drugs to clinical trials.

Report this publication

Statistics

Seen <100 times